Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
September 23, 2019
Medicon Valley Alliance

MVA-member company, Genmab, presents new data on next-generation treatments for multiple sclerosis

MVA-member company, Genmab, presents new data on next-generation treatments for multiple sclerosis

In Stockholm, Sweden, the The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) recently gathered experts and companies working on multiple sclerosis.  Among the presenters were the Danish antibody developer Genmab, which presented results from its drug ofatumumab, which is licensed to Novartis.
In two phase III trials, the ability of the antibody drug to prevent relapse proved vastly superior to that of teriflunomide, an oral drug routinely used to treat relapsing forms of multiple sclerosis. A very promising result indeed for the patients, and MVA would like to congratulate our member company, Genmab, with yet another groundbreaking result!
Read full Labiotech-article here  

The post MVA-member company, Genmab, presents new data on next-generation treatments for multiple sclerosis appeared first on MVA.

Last updated:
September 23, 2019

Medicon Valley Alliance

Medicon Valley Alliance (MVA) is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley, which is a part of Greater Copenhagen. Our 245 members, who together employ approximately 140.000 people, represents the region’s triple helix and include universities, hospitals, human life science business, regional governments and service providers.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

In Stockholm, Sweden, the The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) recently gathered experts and companies working on multiple sclerosis.  Among the presenters were the Danish antibody developer Genmab, which presented results from its drug ofatumumab, which is licensed to Novartis.
In two phase III trials, the ability of the antibody drug to prevent relapse proved vastly superior to that of teriflunomide, an oral drug routinely used to treat relapsing forms of multiple sclerosis. A very promising result indeed for the patients, and MVA would like to congratulate our member company, Genmab, with yet another groundbreaking result!
Read full Labiotech-article here  

The post MVA-member company, Genmab, presents new data on next-generation treatments for multiple sclerosis appeared first on MVA.

Last updated:
September 23, 2019

Medicon Valley Alliance

Medicon Valley Alliance (MVA) is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley, which is a part of Greater Copenhagen. Our 245 members, who together employ approximately 140.000 people, represents the region’s triple helix and include universities, hospitals, human life science business, regional governments and service providers.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail